{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-062739","form_type":"8-K","ticker":"LITS","cik":"0001262104","company_name":"Lite Strategy, Inc.","filed_at":"2024-05-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.646111+00:00","generated_at":"2026-06-01T10:28:13.649922+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"low","headline":"MEI Pharma presents voruciclib Phase 1b AML data at Brookline Symposium","bullets":["CMO Richard Ghalie discussed voruciclib clinical data at virtual MDS/AML symposium on May 21, 2024.","Voruciclib is an oral CDK inhibitor; ongoing Phase 1b in relapsed/refractory AML targeting resistance mechanisms.","Specific efficacy/safety results are detailed in the attached corporate presentation (Exhibit 99.1) but not excerpted in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-062739","json":"https://secwatch.observer/filing/0000950170-24-062739.json","markdown":"https://secwatch.observer/filing/0000950170-24-062739.md","text":"https://secwatch.observer/filing/0000950170-24-062739.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024062739/0000950170-24-062739-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1262104/000095017024062739/meip-20240521.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T10:28:13.649922+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}